Literature DB >> 1701340

Eosinophil accumulation in rats injected with Sephadex particles.

R M Cook1.   

Abstract

Intravenous injection of Sephadex G200 particles into rats on days 0, 2 and 5 caused an increase in eosinophil numbers in blood and lung tissues. Peak numbers were obtained on days 3-12 and thereafter declined to approach control values by day 21. The rise in eosinophil numbers was paralleled by an increase in lung cell fragility as measured by a transient reduction in the number of viable cells isolated from parenchymatous tissue following the digestion of lung fragments in vitro. This decrease in lung cell viability was not seen in rats given a single injection of Sephadex. Dexamethasone, dapsone and isoprenaline given before each injection of Sephadex reduced lung and blood eosinophil numbers and prevented lung cell death. Aspirin and indomethacin were without effect. Incubation of normal lung tissues with disrupted peritoneal eosinophils reduced the numbers of viable cells recovered. No such effects were seen using intact eosinophils and disrupted or intact neutrophils and mononuclear cells. This system provides a model of lung cell damage associated with eosinophil infiltration in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701340     DOI: 10.1111/j.1365-2222.1990.tb03143.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  3 in total

1.  Effects of dexamethasone in a model of lung hyperresponsiveness in the rat.

Authors:  V Piercy; J R Arch; R C Baker; R M Cook; P A Hatt; B A Spicer
Journal:  Agents Actions       Date:  1993-07

2.  Allergen-induced airway responses in rats pretreated with Sephadex.

Authors:  P Rossi; L Xu; N S Wang; J G Martin
Journal:  Agents Actions       Date:  1993-11

3.  Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model.

Authors:  A M Das; T J Williams; R Lobb; S Nourshargh
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.